This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ZP PTH (Weekly)

Zosano Pharma Corporation

Drug Names(s): AK-159, teriparatide, Teribone transdermal patch

Description: ZP PTH (Weekly) is the weekly patch of ZP PTH (Daily).

AK-159 patch delivers PTH 1-34, teriparatide (PTH), a compound that stimulates formation of new bone and reduces the risk of fractures. The titanium microneedle patch delivery technology transmits the drug into the superficial skin layers through a self-administered applicator.

Deal Structure: Zosano and Asahi Kasei
In October 2011, Zosano Pharma and Asahi Kasei Pharma (AKP) announced that they have entered into a long-term strategic collaboration for the development, commercialization and supply of a weekly transdermal patch formulation of Teribone (teriparatide acetate), AKP's formulation of human parathyroid hormone (human PTH 1-34), for the treatment of osteoporosis patients with a high risk of fracture.

Under the terms of the agreement, AKP has received exclusive rights to develop and commercialize the transdermal patch formulation of Teribone in Japan, Korea, China and Taiwan. AKP is responsible for clinical and regulatory development and commercialization activities. The transdermal patch product uses Zosano's patented, clinically validated, and GMP manufactured microprojection technology (ZP Patch Technology) to administer human PTH (1-34) through the skin.

As part of the agreement, AKP has paid Zosano $7.5 million in upfront consideration. In...See full deal structure in Biomedtracker


ZP PTH (Weekly) News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug